BRISTOL-MYERS SQUIBB COMPANY Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- BRISTOL-MYERS SQUIBB COMPANY treasury stock, value, acquired, cost method for the quarter ending 2022-03-31 was $4.25B.
- BRISTOL-MYERS SQUIBB COMPANY treasury stock, value, acquired, cost method for the quarter ending 2020-06-30 was $1.40B.
- BRISTOL-MYERS SQUIBB COMPANY treasury stock, value, acquired, cost method for the quarter ending 2013-12-31 was $0.00, a 100.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY treasury stock, value, acquired, cost method for the quarter ending 2013-09-30 was $49.00M, a 95.28% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY treasury stock, value, acquired, cost method for fiscal 2013 was $413.00M, a 82.84% decline from fiscal 2012.
- BRISTOL-MYERS SQUIBB COMPANY treasury stock, value, acquired, cost method for fiscal 2012 was $2.41B, a 96.33% increase from fiscal 2011.
- BRISTOL-MYERS SQUIBB COMPANY treasury stock, value, acquired, cost method for fiscal 2011 was $1.23B, a 108.86% increase from fiscal 2010.
- BRISTOL-MYERS SQUIBB COMPANY treasury stock, value, acquired, cost method for fiscal 2010 was $587.00M.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2022-03-31 | $4.25B 10-Q · filed 2023-10-26 | |
| 2020-06-30 | $1.40B 10-Q · filed 2021-10-27 | |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-14 | $413.00M 10-K · filed 2014-02-14 |
| 2013-09-30 | $49.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-23 | $906.00M derived: sum of 4 quarters · filed 2014-07-24 |
| 2013-06-30 | $66.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-24 | $1.90B derived: sum of 4 quarters · filed 2014-07-24 |
| 2013-03-31 | $298.00M 10-Q · filed 2014-04-29 | $2.38B derived: sum of 4 quarters · filed 2014-04-29 |
| 2012-12-31 | $493.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-14 | $2.41B 10-K · filed 2014-02-14 |
| 2012-09-30 | $1.04B derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-23 | $2.28B derived: sum of 4 quarters · filed 2014-02-14 |
| 2012-06-30 | $552.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | $1.72B derived: sum of 4 quarters · filed 2014-02-14 |
| 2012-03-31 | $323.00M 10-Q · filed 2013-04-25 | $1.41B derived: sum of 4 quarters · filed 2014-02-14 |
| 2011-12-31 | $368.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-14 | $1.23B 10-K · filed 2014-02-14 |
| 2011-09-30 | $472.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $1.08B derived: sum of 4 quarters · filed 2012-10-24 |
| 2011-06-30 | $248.00M 10-Q · filed 2011-07-28 | $800.00M derived: sum of 4 quarters · filed 2012-04-26 |
| 2011-03-31 | $138.00M 10-Q · filed 2012-04-26 | $725.00M derived: sum of 4 quarters · filed 2012-04-26 |
| 2010-12-31 | $225.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | $587.00M 10-K · filed 2012-02-17 |
| 2010-09-30 | $189.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | |
| 2010-06-30 | $173.00M 10-Q · filed 2011-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |